<SEC-DOCUMENT>0001564590-21-016112.txt : 20210329
<SEC-HEADER>0001564590-21-016112.hdr.sgml : 20210329
<ACCEPTANCE-DATETIME>20210329160219
ACCESSION NUMBER:		0001564590-21-016112
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210329
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210329
DATE AS OF CHANGE:		20210329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frequency Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001703647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472324450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39062
		FILM NUMBER:		21781690

	BUSINESS ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY, SUITE 203
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-315-4600

	MAIL ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY, SUITE 203
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>freq-8k_20210329.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-8k_20210329.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): March 29, 2021</p>
<p style="text-align:center;margin-top:6pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware </p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47-2324450</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19 Presidential Way, 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> Floor </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Woburn, MA 01801</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) (Zip Code) </p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(866) 389-1970&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, include area code) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">N/A</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;line-height:4pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)<font style="font-size:6pt;font-weight:normal;color:#000000;">&#160;</font></p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, par value $0.001 per share</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FREQ</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Global Select Market</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:64.81%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#9746; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 2.02. Results of Operations and Financial Condition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2021 Frequency Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and year ended December 31, 2020 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following exhibit relates to Item 2.02, which shall be deemed to be furnished, and not filed: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:6.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  style="width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:91.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex991_6.htm"><font style="text-decoration:underline;">Press Release issued on March 29, 2021</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:91.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:51.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:51.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 29, 2021</p></td>
<td valign="bottom"  style="width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:47.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David L. Lucchino</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:47.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:47.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>freq-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk20845026"></a><img src="gce10ol4ip4v000001.jpg" title="" alt="" style="width:268px;height:45px;"><a name="_Hlk20845026"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter<br /> and Full Year 2020 Financial Results</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Recent FX-322 Study Readouts Support Single-Dose Administration as Part of Future Trial Designs; <br />Company Planning Additional Single Injection Studies </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"> Results from Exploratory FX-322 Phase 1b Studies in Patients with Age-Related and Severe Hearing Loss <br />Anticipated in Q2 and Q3 Respectively</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Company Ends Year with $220 Million in Unrestricted Cash Providing Runway Into 2023</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63932766"></a>WOBURN, Mass., March 29, 2021<a name="_Hlk63932766"></a>&#160;&#8211;&#160;<font style="font-weight:normal;">Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the fourth quarter and year ended December 31, 2020.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We recently obtained valuable data from two clinical studies in patients with sensorineural hearing loss that have provided us with important learnings that already are informing our future development plans for FX-322, specifically around trial design and using a single administration approach in our studies,&#8221; said David L. Lucchino, Frequency&#8217;s President and CEO. &#8220;Combined with data from our published Phase 1/2 results, we have now shown statistically significant and clinically meaningful improvements in speech intelligibility from two independent, single injection studies that we believe provide encouraging support for FX-322 as a potential novel treatment option as we drive forward in this new area of regenerative medicine.&#8221; </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Lucchino continued: &#8220;Upcoming readouts from our ongoing studies will be further clarifying, and&nbsp;&nbsp;we will use these insights as we plan for future placebo-controlled FX-322 clinical studies using a single administration regimen. We have utilized a multi-study development approach that enables us to continually learn more about the clinical profile of FX-322, its potential application in different potential populations, as well as how to carry out trials most effectively in this emerging therapeutic area. In Q2, we anticipate results of a FX-322 Phase 1b study in patients with age-related hearing loss and in Q3 results of a FX-322 Phase 1b study of patients with severe sensorineural hearing loss, which will further inform our path forward. There is a tremendous need to advance the standard of care for people with sensorineural hearing loss, and we are are grateful to the patient community and all of those that have participated in our clinical studies for their continued support as we work to advance a medicine for hearing restoration.&#8221;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">FX-322 Day-90 Study Detail and Ongoing Program </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FX-322 Phase 2a Study Day 90 Topline Results</font><font style="color:#000000;">: The Company recently shared interim data from its four-arm, Phase 2a study of FX-322 conducted in 95 subjects aged 18-65 with mild to moderately severe sensorineural hearing loss (SNHL). In the study, all subjects were administered a total of four weekly intratympanic injections comprised of zero, one, two, or four </font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:8pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="color:#000000;">doses of FX-322 with the balance of injections comprised of placebo doses. </font><font style="color:#000000;">S</font><font style="color:#000000;">ubjects were evaluated for hearing improvement using </font><font style="color:#000000;">Word Recognition (WR), </font><font style="color:#000000;">Words-In-Noise</font><font style="color:#000000;"> (WIN), pure tone audiometry and additional exploratory measures</font><font style="color:#000000;">.</font><font style="color:#000000;"> While WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single-injection studies. The Phase 2a interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards, suggesting bias due to trial design. Given these challenges observed in the Phase 2a study design, there was no discernible hearing benefit of FX-322 over placebo. </font><font style="color:#000000;">No treatment-related serious adverse events were observed in the study. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FX-322 - 111 Phase 1b:</font><font style="color:#000000;"> The Company also shared preliminary data from a recently completed open-label, single-dose study of FX-322 (FX-322-111) designed to evaluate the impact of injection conditions on tolerability. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322, with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. At day 90 following dosing, thirty-four percent (34%) of subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p &lt;0.05). This included a subset of subjects that more than doubled their WR scores. These data were based on results from 32 of 33 subjects that completed the 90-day clinical assessment period. The single dose had a favorable safety profile and was well tolerated. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FX-322 - 112 Phase 1b Study in Age-Related Hearing Loss</font><font style="color:#000000;">:&nbsp;&nbsp;In October 2020, Frequency commenced a Phase 1b safety study of FX-322 (FX-322-112) for individuals with age-related hearing loss. The study, which has completed enrollment, is a double-blind, placebo-controlled, randomized, multicenter safety study of 30 individuals aged 66-85 with age-related hearing loss. The primary objectives of the Phase 1b study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. Study participants were randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, WIN and pure tone audiometry are being evaluated. Safety, otologic and audiologic assessments are also being conducted at day 30 and 90 following administration of FX-322 or placebo. Frequency expects to obtain topline results from this study in Q2 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FX-322 - 113 Phase 1b Study in Severe SNHL: </font><font style="color:#000000;">In November 2020, Frequency commenced a Phase 1b study in patients aged 18-65 with severe SNHL (FX-322-113). Enrollment is continuing for the study of up to 30 individuals. This study employs a similar design and endpoints to the ongoing age-related Phase 1b study. Frequency expects to obtain topline results from this study in Q3 2021.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Other FX-322 Program Highlights </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FX-322 Phase 1/2 Publication and Presentation: </font><font style="color:#000000;">In February 2021, the results from the completed FX-322 Phase 1/2 study were published in </font><font style="font-style:italic;color:#000000;">Otology &amp; Neurotology</font><font style="color:#000000;">, a leading peer-reviewed journal focused on disorders of the ear. The data demonstrate hearing improvements </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="color:#000000;">in adults with acquired </font><font style="color:#000000;">SNHL</font><font style="color:#000000;">, and the first known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy. The Phase 1/2 study data were also presented at the leading international hearing research conference, the Association for Research in Otolaryngology (ARO) 44th Annual Midwinter Meeting on February 22, 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Key Opinion Leader Webcast on Potential for Restorative Treatments for SNHL</font><font style="color:#000000;">: In January 2021, Company management and leading hearing loss researchers and clinicians held an investor </font><font style="text-decoration:underline;color:#000000;">event</font><font style="color:#000000;"> to discuss current interventions for the treatment of acquired sensorineural hearing loss (SNHL), unmet medical needs for hearing loss patients and the potential of FX-322 to transform the current standard of care. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FX-322 Phase 1/2 Durability Data:</font><font style="color:#000000;"> In September 2020&#160;at the American Academy of Otolaryngology&#160;&#8211; Head and Neck Surgery (AAO-HNS) Annual Meeting, data from a Phase 1/2 follow-up study showed that some patients with chronic SNHL had maintained significant improvements in key measures of hearing following a single injection of FX-322. Susan King, M.D., FACS, the lead investigator on both studies, outlined data which showed sustained improvements 13 &#8211; 21 months after initial dosing in measures of speech intelligibility (clarity) and in some patients, increased audibility (volume) threshold values at the highest tested frequency.&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Clinical Data from Exploratory Study Confirming Delivery of FX-322 to the Cochlea: </font><font style="color:#000000;">In May 2020, the Company announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent the active agents of FX-322 from reaching the cochlea. Further, the levels of FX-322 in the cochlea were predicted to reach the therapeutically active range of the treatment.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">2020 and Recent Business Activity:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Expanded Leadership Team: </font><font style="color:#000000;">The Company recently has made several important leadership hires, building out its finance, manufacturing and pre-commercial functions:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Peter P. Pfreundschuh was appointed to the role of Chief Financial Officer in December 2020 to oversee the Company&#8217;s financial strategy and activities related to accounting, investor relations, business development and business operations. He joined Frequency from UroGen Pharma Ltd., where he served as Chief Financial Officer, Chief Compliance Officer and Corporate Secretary. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Quentin McCubbin, Ph.D. was appointed as Chief Manufacturing Officer in January 2021.&#160;Dr. McCubbin&#160;is overseeing Company technical operations, leading drug product formulation, chemistry manufacturing and controls (CMC) and supply chain, to support the development of Frequency&#8217;s pipeline of product candidates. He joined Frequency from Cerevel Therapeutics, a clinical-stage biotechnology company where he served as Head of Technical Operations. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Kevin Franck, Ph.D. was appointed to the role Senior Vice President of Strategic Marketing and New Product Planning in February 2021. Dr. Franck will lead pre-commercial strategy and launch planning for Frequency&#8217;s clinical pipeline. A licensed audiologist, Dr. Franck </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="color:#000000;">joined Frequency from Massachusetts Eye and Ear, where he served as Director of Audiology and </font><font style="color:#000000;">was on the </font><font style="color:#000000;">Harvard Medical School </font><font style="color:#000000;">f</font><font style="color:#000000;">aculty </font><font style="color:#000000;">in</font><font style="color:#000000;"> the Department of Otolaryngology-Head and Neck Surgery.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Progress on Remyelination Program for Multiple Sclerosis: </font><font style="color:#000000;">The Company continues to advance preclinical programs to support the advancement of a therapeutic candidate for remyelination in multiple sclerosis into the clinic. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Fourth Quarter 2020 Financial Results</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Position: <font style="font-weight:normal;">Cash, cash equivalents and short-term investments on Dec. 31, 2020 were $220.3 million.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on current plans and assumptions, the Company expects its existing cash and cash equivalents, and short-term investments will be sufficient to fund its operations into 2023. This guidance does not include potential future milestones which could be received from Astellas Pharma for continued FX-322 development.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue: <font style="font-weight:normal;">Revenue was $10.0 million and $37.0 million for the three- and twelve-month periods ended Dec. 31, 2020, respectively. The Company had revenue of $4.7 million and $28.9 million in each of the comparable periods of 2019.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; Development Expenses: <font style="font-weight:normal;">Research and development expenses were $11.8 million and $37.4 million for the three- and twelve-month periods ended Dec. 31, 2020, respectively, as compared to $6.2 million and $18.8 million for the comparable periods of 2019. The increases are due to increased costs related to the Company&#8217;s lead product candidate, FX-322, including external development costs related to the Company&#8217;s ongoing Phase 2a clinical trial, as well as increased personnel-related costs due to additional headcount to support the growth of Frequency&#8217;s research and development organization.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses: <font style="font-weight:normal;">General and administrative expenses were $8.4 million and $27.1 million for the three- and twelve-month periods ended Dec. 31, 2020, respectively, as compared to $5.0 million and $14.8 million for the comparable periods of 2019. The increases are primarily due to an increase in personnel-related costs, including stock-based compensation, for additional headcount required to support the growth of the Company as well as costs associated with being a public company, primarily comprised of insurance, consulting and professional fees.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss<font style="font-weight:normal;">: Net loss was $10.2 million and $26.5 million for the three- and twelve-month periods ended Dec. 31, 2020, respectively, as compared to $5.5 million and $18.7 million for the comparable periods of 2019. The increase in net loss in 2020 reflects the increase in research and development costs associated with the growth of Frequency&#8217;s research and development organization and the increase in general and administrative expenses required to support the growth of the Company and the cost associated with operating as a public company.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Frequency Therapeutics</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company&#8217;s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company&#8217;s lead product candidate, FX-322, is designed to regenerate auditory </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headquartered in Woburn, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit&#160;<font style="text-decoration:underline;">www.frequencytx.com</font>&#160;and follow Frequency on Twitter @Frequencytx.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the interpretation and implications of the results of the interim day-90 Phase 2a data and the FX-322-111 data, including advancing FX-322 as a single-dose regimen and re-treatment at longer intervals, the impact of the trial design of the Phase 2a study on clinical data, the timing of results of the Company&#8217;s clinical studies, the treatment potential of FX-322, the ability of our technology platform to provide patient benefit, estimates of the size of the hearing loss population and population at risk for hearing loss, the Company&#8217;s ability to advance its hearing program and further diversify its portfolio, the timing of the Company&#8217;s remyelination program, the sufficiency of the the Company&#8217;s capital resources, the license and collaboration with Astellas Pharma Inc., and the potential application of the PCA platform to other diseases.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Company&#8217;s ongoing and planned clinical trials, research and development and manufacturing activities, the relocation of the Company&#8217;s offices and laboratory facilities, the Company&#8217;s business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Company&#8217;s need for additional funding to complete development and commercialization of any product candidate; the Company&#8217;s dependence on the development of FX-322; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; costly and damaging litigation, including related to product liability or </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with laws and regulations, including healthcare and environmental, health, and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property; security breaches or failure to protect private personal information; attracting and retaining key personnel; and ability to manage growth.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other important factors discussed under the caption &#8220;Risk factors&#8221; in the Company&#8217;s Form 10-K filed with the Securities and Exchange Commission (SEC) on March 29, 2021 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management&#8217;s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date of this press release.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:109.78%;">
<tr style="height:19.8pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67903589"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.65pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,828</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,196</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,415</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.65pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,277</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,488)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,550</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.65pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,257</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.65pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:24.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:13.65pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:24.85pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:37.6pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,807,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,409,518</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet Data</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198,430</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,575</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,722</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,231</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,860</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Contacts<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Contact:<br />Carlo Tanzi, Ph.D.<br />Kendall Investor Relations<br /><font style="text-decoration:underline;">ctanzi@kendallir.com</font><br />617-914-0008</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:<br />Suzanne Day</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel: 781-496-2211</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="text-decoration:underline;">sday@frequencytx.com</font>&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gce10ol4ip4v000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gce10ol4ip4v000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "0 T<# 2(  A$! Q$!_\0
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M_+/^)C,E_P"B<S3_ ,*L)_D?T-_Q([Q7_P!%SP__ .&[,O\ Y+U_IZ?PH?\
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MV7C.;6/$L.H:M#XAU63Q'!J3ZAKD6JZG%JUVTU_'J%ZMP+F3_3BK^83_ (.
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M7_LH,R_]5T3^I#_@W:_Y,I^*'_9TGC7_ -5-\$J_>ROP3_X-VO\ DRGXH?\
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MSJ_O?9P*_C+_ .#B7_D];X7_ /9K?@K_ -6S\;:_LTK^1W_@X\^&O]E_&O\
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M_P"Q7F?_ *;@?S]],#_DS&._[*#(?_4BH?@G17[V?\&[7_)ZWQ0_[-;\:_\
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M9^/_  FFH_:_V@/A#_9?A_XT?9_#/_"/:3K']MW.O_\ "">.=(^Q37.A3?\
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MXZI]7PE.&84:==4L90H1KT*->$X4<7B::55_V2T5_&U_PU!^TM_T</\ '/\
M\.UX^_\ F@H_X:@_:6_Z.'^.?_AVO'W_ ,T%>)_Q.QPO_P!$3G__ (<,N_\
MD3Z3_BG#QM_T<CA;_P -.;?_ "1_9+17\;7_  U!^TM_T</\<_\ P[7C[_YH
M*/\ AJ#]I;_HX?XY_P#AVO'W_P T%'_$['"__1$Y_P#^'#+O_D0_XIP\;?\
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M5_9I7\9?_!NU_P GK?%#_LUOQK_ZMGX)5_9I1X[?\E_B/^Q7EG_IN8OH??\
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M.%.'-)<TYQ@KRDD_ZXJ*^6_^&Y/V*?\ H\']EO\ \2!^$W_S6T?\-R?L4_\
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MTV#^S?!?PZO?%/C'6MES>0R7G]CZ#??V=IZ76K:A]ETNQOKRW_EO_P""K_\
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M.#PU90G6H\LG2KUH5%&7V9<MGT;/J2BOEO\ X;D_8I_Z/!_9;_\ $@?A-_\
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M4#\*Z_<_H\_\EIF?_9+XW_U;9(?R)]-K_DU7#_\ V<'*O_6<XK/U(_X-K?\
MF]'_ +MT_P#>[5_4A7\M_P#P;6_\WH_]VZ?^]VK^I"OE_&?_ ).5Q)_W1_\
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M1-<T35OB=XHO]*UC1]5L)KBPU/2]3L;B"]T_4+*>>TO;2>&YMII(9$=O9O\
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M'UW_ !/E]'[_ *&/%/\ XC.)_P#EQ_.!17]'_P#PY^_9I_Z'CXY_^%+X!_\
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MF^*CA$YTJKP-/"O$X;#XIUJ:****_;C^;0HHHH **** "BBB@ HHHH ****
M/\UK]IK]GSQM^S!\:_'WP>\:Z3XIM/\ A%_%/BK3O"7B+Q1X-U;P/_PL?P3H
MGBS7_"^@_$KP[I&K/<^=X6\7_P#"/W5]I%_INIZWI,FVXMK/6M2^R27#?W#?
M\$C_  -XV^&W_!/;]G[P5\1?!_BGP#XQT7_A:W]L>$O&OA_5O"WB;2?[1^-W
MQ)U;3_[2T'7+2QU2P^W:7?6.I6?VJUB^U:?>6MY!OM[B&1_T?HK]:XZ\5\7Q
MQP_EF28K*:6#JX+&T,?B<?#&.L\9B*&$Q.$3AAEA,/#"QFL75JU(JI77-R1A
M[.*:E_-OA#]'++?"/C3/N+,OXEQ&9X?-<KQ>3X#)ZF6+"K+,%B\RP&8RC5Q\
MLQQM7,*E%Y=AZ%&HZ&$?LW5G65:I*+@4445^2G])!1110 5_(3_P<5_"[X@P
M?M#?!_XU/X4U5OA7J?P9T+X76WCB&..XT2/X@Z'XW^*/BR]\*:A+!+)-I.JS
M^'/$-AJ^CQZK#91>(;2WUQM EU-_#'B5-)_KVHKZ[@?BRKP5Q!A\]IX*GF"I
M4<1AZN$G6EAG4I8BGROV>(C3K>RJ1DH24I4*T7%2BX7DIQ_-/%KPWP_BKP7C
M>$*^:ULE>(Q6"QN'S&EA88Y4,1@JZJ1]M@YUL*\31G!U(2IPQ>%FIRA456T)
M4ZG\F7_!N_\  +XHVGQ@^*G[1VJ^&=5T/X5W'P9N_AUX:U_6]%\0Z9:>/-;\
M3_$?0[^>Z\!:K<Z,OASQ1I?A";X3:_H_C:>PUQKO0-;U/P]I[V-PU[>OIO\
M6;114\:\5U^,^(,5GM?"T\#[:G0H4<)3J.NJ%##TU"$)5W3I.M4;YISJ>RII
MRE:-.$4HK3PI\.<'X5\%Y?PA@\PK9L\+6Q>+Q>95J$<*\7C,;6=6M4IX2-;$
M1PM&,>2E2H?6*\HPIISK5*DI3967KFAZ)XGT36/#7B71]+\0^'/$.EZAH>OZ
M!KFGVFK:)KFB:M:36&JZ/K&E7\-Q8:GI>IV-Q/9:AI][!/:7MI/-;7,,D,CH
MVI17RD92C)2BW&46I1E%M2C).Z::U33U36J>J/T6<(U(2IU(QG"<90G"<5*$
MX23C*,HR34HR3:E%IIIM-6/\\']OS]B7X@_L/?';7_ 6OZ1JLGPS\0ZKK^L?
M _QY=7,6K6GC;X?0:EC3X;[6[/2-#L6\?>&+"]TK3/B+H::1I,NEZW/!JEAI
M\GA#Q#X1UO6_Z/O^#?3X@?';7OV<_'?P]^(7A?5;'X+?#[5=%U#]GOQAJ'@S
M4M"M/$=IXV\2?$VZ^*.AZ'XM:WM=%\<Z7X5\;Z(UW--:+J&M^'-;\4ZQHVLZ
MQ+IJ^&]&T'^@"BOV'BCQ=Q/%G"%+AK-,BPL\?">#J2SQXN4W[?"3_P!ZP^!>
M%7U?%8B@YX>O46,J0<,1BN2E"%:-.E_,?A]]&C ^&_B;B./.'^,,PI9-5IYI
M0I\)++H4XO"9G25LOQN;QS!_7LOP6,5+&X2@\KHU8U<%ESK8BK4PLZV(****
M_'3^GC^%#_@MUX&\;:#_ ,%"?C/XUUSP?XIT7P=X^_X5U_P@OBW5O#^K:=X9
M\:?\(M\$?A/I/B?_ (1+7KRTATOQ'_PCFJS0Z;KW]CW5Y_9&H2QV>H?9[AUC
M/Y'5_J045_160>/T\ER3*,GJ<*1Q<LJR[!Y<L3#.Y895X8+#T\-2J.A+*<2Z
M<Y4Z<'->WFG/FE'EBU"/\0<9?0RI<5<6\2\3T?$6IEL.(L\S3/'@*O"<<?+"
M5<VQE;'5Z"QD.(\ J].G7KU%1D\)2DJ7)"?/.,JD_P#+?HK_ %(**];_ (F1
M_P"J,_\ -B__  $?-?\ $B?_ %=/_P TC_\ &\_RWZ_JY_X-PO WC;0?#/[4
MGC77/!_BG1?!WC[_ (4C_P (+XMU;P_JVG>&?&G_  BVH?'+2?$__"):]>6D
M.E^(_P#A'-5FATW7O['NKS^R-0ECL]0^SW#K&?Z9Z*^5XU\;)\7\-X_AZ'#<
M<MCCYX1U<7+-I8UPAA,90QJC"BLMP:YYU,/3BYRJR48.:Y')QE']%\*/HGTO
M#/CK)^-JG'=3/9Y-3S)4,NAPU'*8U:N8Y9C,J<ZV*EGN9MTZ5#'5JBI0P\)3
MJJDW6C",X5"BBBOPD_K\*_FM_;\_X(.Z)XVN]?\ BU^Q1+I?A'Q7J>JZ_P"(
M_$OP)\1:E::+\/KZ)]$^V0:;\&+RVT98?!.JZAXCL9XK;PAXLU)/A\LOBM8]
M)\2?"_PGX1LM!U#^E*BOI.&.+<]X0Q_]H9'C'AYS488G#U%[7!XRG%MQIXK#
MMJ-51YI>SFG"M1<I.C5IRDV_A/$#PWX1\3<F_L7BW+(XRE2E.I@<;1DL/F>5
MUYJ*G7R[&J,JE"514Z:K4I*IA<2J=..*H5X0C%?YM_QY_9!_:<_9BN[B#X[?
M!+Q]\/;"WU73-#3Q5J&CMJ?P^U'6]8T1_$5AH^A_$KP_)JWP_P#$.JR:1!>7
M,VGZ%XEU&[LY=,UBRO8;>_T;5;:S^;Z_U(*\$\:_LJ_LO?$GQ-J7C7XB_LW?
M 3Q]XQUK['_;'BWQK\'OA[XI\3:M_9VGVNDZ?_:6O:YX=OM5O_L.EV-CIMG]
MJNI?LNGV=K9P;+>WAC3][RSZ1LE3C#.>&5*JJ?OXC+,>X4ZE7W%:.#Q5&<J5
M-^_*[Q]:4;0ARRNYK^.,_P#H-P=:I5X6X^E##RK6I8+/\G56M1P[]H^:IFF7
M8JC3Q-:/[J'+')\)"=ZE3GIVC2E_FM5^C_[(_P#P2R_:W_:P\3>%OL?PV\4_
M"WX2ZQ_PC6KZQ\:?B-X<O?#WAFV\$^)M/OM9T_Q1X'TK7)=#U7XL_P!IZ5I[
M?V);^!?M^DR:AJOAK_A)_$7A'P_KL/B6#^YOX=?LX_L\_"#6[KQ+\)?@-\&?
MA=XCOM+GT.]U_P"'7PN\$>"=;O-$N;NQO[G1[K5?#6AZ9?W&EW%]IFFWL^GR
MSO:2W>GV-S)"TUI \?LU<N>?2)QE:A5H</Y#3P5:=-QAC\QQ*Q<Z,I*SG3P5
M*C2I.I3UE2E5Q%:DY\KJX><(RIS]#A+Z$.687&8?%\:<8ULVPU*M&I5R?(\
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M]*L(;B^U/5=3OKB"RT_3[*">[O;N>&VMH9)I$1O]&?\ X8<_8I_Z,^_9;_\
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M>-:C4J825;#K%49+GI5:'UBA*4*CE"M3G&,E_EOT5_J045^Z?\3(_P#5&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZG_RT/\ B8#QG_Z.'Q#_ .#J'_S/_7S9^]G_ !$2_MK?]$O_ &6__"*^+/\
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MX=UHT,174O[V****_B<_U?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML(5?JF*]CNT445^@'Y4%%?*?[8/[3G_#*/PTT/XB?\(1_P )[_;/CK3/!?\
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M]#^,O_B':_;6_P"BH?LM_P#A:_%G_P"<E1_Q#M?MK?\ 14/V6_\ PM?BS_\
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M/A\TA&<7AZ]:I.-.=:-"G[>--1;=*GS\W+&Q7\X'_!8'_DY;P/\ ]D,\-?\
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M??P?\&_A#\/-3GUKP!\*OAOX&UFZL9=+N=6\'^!O#'AG4[C3)KBUNYM.GO\
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M\#Z,'_)C.!_^[E_]:_B ^I^FE_RDQXE?]V=_ZP'"IRGC#P'X'^(>F0:+X_\
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M>(HTL,UE&%S#%2JPJ_O)4<51HPC%J<9.3L?T8^#_  'X'^'FF3Z+X \&>%/
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M<@H9-AI4*M1PBL#]4QF,P\N2=^>ES4IQ3YE!Q=S^(_&3P4XK\+HY=G'$O&G
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M5JEO=6-U]EOK6UO;;SX)/(N[:"YBVS0QNO\ 2Y_PS!^S3_T;Q\#/_#2> ?\
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>$HHHK^HS^* HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
